Drug Topics - May 12, 2008 - (Page 8)

8 DRUG TOPICS MAY 12, 2008 www.drugtopics.com Latebreakers erectile dysfunction is excluded from the program. Among other changes the rule also ensures payment for administration of covered vaccines. The final rule was published in the April 15 Federal Register. nostril administered twice daily, demonstrated significantly greater decreases in total nasal symptom scores (TNSS)—a combination of stuffy, runny, itchy nose, and sneezing—compared with placebo nasal spray. The most common adverse effects experienced were bitter taste, headache, epistaxis, pharyngolaryngeal pain, cough, urinary tract infection, post-nasal drip, and cough. from instituting a 10% across-theboard cut in payments to MediCal providers. The cuts, which are set to go into effect in July, are part of an effort to cover an estimated $10 billion, for the next fiscal year. The City of San Francisco has also stated that it may challenge the cuts. Joining the two pharmacies in the suit were the Independent Living Center of Southern California, a nursing facility; and the Gray Panthers, an advocacy group. The suit also sought to stop the state from suspending for four months its share of payments to poor recipients. According to the complaint, a reduction in payments would cause many healthcare providers to stop taking Medi-Cal patients. New allergy nasal spray cleared by FDA Olopatadine HCl (Patanase, Alcon) nasal spray has received a regulatory green light for the relief of symptoms associated with seasonal allergic rhinitis. The spray is indicated for patients 12 years of age and older and has a 30-minute onset of action and a 12-hour duration. The approval was based on clinical studies that showed olopatadine, as two sprays per Lawsuit aims to stop Medi-Cal cuts Uptown Pharmacy and Gift Shop and Central Pharmacy, both based in the Los Angeles area, have joined with a nursing facility and an advocacy group in a suit to stop the state of California http://www.drugtopics.com

Table of Contents Feed for the Digital Edition of Drug Topics - May 12, 2008

Drug Topics - May 12, 2008 Contents Latebreakers Letters R.Ph.s Say More Needs to be Done to Prevent Pediatric Drug Errors There's a New School of Thought on Use of Beta-Blockers for Hypertension Cover Story Guest Spot Letters Clinical Practice Special Report Professional Practice Broad Label for New Leukemia Therapy Looks Promising Treating Asthma During Pregnancy Safer than Not, Says New Guide In the Pipeline Clinical Q&A APhA Leader's Plan to Leave Office Takes Center Stage at its Conference Policies Passed at a Glance Giving a Talk to the Community? Check Out These Materials This Foundation has Funds to Spare JP at Large Cover Story: Employers and R.Ph.S: A Win-Win Combo FDA's Ilisa Bernstein Discusses Pharmacy Affairs Legal Q&A Manufacturers Unleash a Rash of Poison Ivy Treatments Are OTC Cold Remedies Safe for Kids? Probiotics are All the Rage: How You Can Capitalize on It CMS' Prices for Round One of DMEPOS Competitive Bidding Raising Concerns CVS Caremark's Mentoring Program Recruits and Retains R.Ph.s Antibiotic Resistance Among Community Pathogens Technology Update New Products Advertisers Index Classified Viewpoint

Drug Topics - May 12, 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.